142 related articles for article (PubMed ID: 36083142)
21. Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study.
Maskew M; Fox MP; van Cutsem G; Chu K; Macphail P; Boulle A; Egger M; Africa FI
PLoS One; 2013; 8(6):e64392. PubMed ID: 23755122
[TBL] [Abstract][Full Text] [Related]
22. AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma.
Reid EG; Shimabukuro K; Moore P; Ambinder RF; Bui JD; Han S; Martínez-Maza O; Dittmer DP; Aboulafia D; Chiao EY; Maurer T; Baiocchi R; Mitsuyasu R; Wachsman W;
Clin Cancer Res; 2022 Jun; 28(12):2646-2656. PubMed ID: 35247913
[TBL] [Abstract][Full Text] [Related]
23. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma.
Kimball LE; Casper C; Koelle DM; Morrow R; Corey L; Vieira J
J Infect Dis; 2004 Jun; 189(11):2016-22. PubMed ID: 15143468
[TBL] [Abstract][Full Text] [Related]
24. Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi.
Herce ME; Kalanga N; Wroe EB; Keck JW; Chingoli F; Tengatenga L; Gopal S; Phiri A; Mailosi B; Bazile J; Beste JA; Elmore SN; Crocker JT; Rigodon J
J Int AIDS Soc; 2015; 18(1):19929. PubMed ID: 26028156
[TBL] [Abstract][Full Text] [Related]
25. Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: a prospective multicohort study.
Rohner E; Valeri F; Maskew M; Prozesky H; Rabie H; Garone D; Dickinson D; Chimbetete C; Lumano-Mulenga P; Sikazwe I; Wyss N; Clough-Gorr KM; Egger M; Chi BH; Bohlius J
J Acquir Immune Defic Syndr; 2014 Dec; 67(5):547-54. PubMed ID: 25393941
[TBL] [Abstract][Full Text] [Related]
26. Navigating the heterogeneous landscape of pediatric Kaposi sarcoma.
Kamiyango W; Villiera J; Silverstein A; Peckham-Gregory E; Campbell LR; El-Mallawany NK
Cancer Metastasis Rev; 2019 Dec; 38(4):749-758. PubMed ID: 31845111
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcomes for children and adolescents with Kaposi sarcoma.
Silverstein A; Kamiyango W; Villiera J; Peckham-Gregory EC; McAtee CL; Scheurer ME; Cox CM; Kovarik CL; Campbell LR; Allen CE; Mehta PS; Kazembe PN; Ozuah NW; El-Mallawany NK
HIV Med; 2022 Feb; 23(2):197-203. PubMed ID: 34634187
[TBL] [Abstract][Full Text] [Related]
28. The clinical application of plasma Kaposi sarcoma herpesvirus viral load as a tumour biomarker: results from 704 patients.
Haq IU; Dalla Pria A; Papanastasopoulos P; Stegmann K; Bradshaw D; Nelson M; Bower M
HIV Med; 2016 Jan; 17(1):56-61. PubMed ID: 26111246
[TBL] [Abstract][Full Text] [Related]
29. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
[TBL] [Abstract][Full Text] [Related]
30. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of a Predictive Staging Model for HIV-Associated Kaposi Sarcoma in Uganda.
Okuku F; Krantz EM; Kafeero J; Kamya MR; Orem J; Casper C; Phipps W
J Acquir Immune Defic Syndr; 2017 Apr; 74(5):548-554. PubMed ID: 28107226
[TBL] [Abstract][Full Text] [Related]
32. Beyond T Staging in the "Treat-All" Era: Severity and Heterogeneity of Kaposi Sarcoma in East Africa.
Freeman EE; Semeere A; McMahon DE; Byakwaga H; Laker-Oketta M; Regan S; Wenger M; Kasozi C; Ssemakadde M; Bwana M; Kanyesigye M; Kadama-Makanga P; Rotich E; Kisuya J; Wools-Kaloustian K; Bassett IV; Busakhala N; Martin J
J Acquir Immune Defic Syndr; 2021 Aug; 87(5):1119-1127. PubMed ID: 33871409
[TBL] [Abstract][Full Text] [Related]
33. Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi.
Gopal S; Liomba NG; Montgomery ND; Moses A; Kaimila B; Nyasosela R; Chikasema M; Dhungel BM; Kampani C; Sanders MK; Krysiak R; Dittmer DP; Fedoriw Y
J Int AIDS Soc; 2015; 18(1):20122. PubMed ID: 26242311
[TBL] [Abstract][Full Text] [Related]
34. Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS).
Polizzotto MN; Uldrick TS; Wyvill KM; Aleman K; Marshall V; Wang V; Whitby D; Pittaluga S; Jaffe ES; Millo C; Tosato G; Little RF; Steinberg SM; Sereti I; Yarchoan R
Clin Infect Dis; 2016 Mar; 62(6):730-738. PubMed ID: 26658701
[TBL] [Abstract][Full Text] [Related]
35. KSHV viral load and Interleukin-6 in HIV-associated pediatric Kaposi sarcoma-Exploring the role of lytic activation in driving the unique clinical features seen in endemic regions.
El-Mallawany NK; Mehta PS; Kamiyango W; Villiera J; Peckham-Gregory EC; Kampani C; Krysiak R; Sanders MK; Caro-Vegas C; Eason AB; Ahmed S; Schutze GE; Martin SC; Kazembe PN; Scheurer ME; Dittmer DP
Int J Cancer; 2019 Jan; 144(1):110-116. PubMed ID: 30204240
[TBL] [Abstract][Full Text] [Related]
36. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
El Amari EB; Toutous-Trellu L; Gayet-Ageron A; Baumann M; Cathomas G; Steffen I; Erb P; Mueller NJ; Furrer H; Cavassini M; Vernazza P; Hirsch HH; Bernasconi E; Hirschel B;
AIDS; 2008 May; 22(9):1019-28. PubMed ID: 18520345
[TBL] [Abstract][Full Text] [Related]
37. Omega-3 decreases IL-6 levels in HIV and human herpesvirus-8 coinfected patients in Uganda.
Coghill AE; Schenk JM; Mahkoul Z; Orem J; Phipps W; Casper C
AIDS; 2018 Feb; 32(4):505-512. PubMed ID: 29381560
[TBL] [Abstract][Full Text] [Related]
38. Population-based assessment of kaposi sarcoma-associated herpesvirus DNA in plasma among Ugandans.
Shebl FM; Emmanuel B; Bunts L; Biryahwaho B; Kiruthu C; Huang ML; Pfeiffer RM; Casper C; Mbulaiteye SM
J Med Virol; 2013 Sep; 85(9):1602-10. PubMed ID: 23852686
[TBL] [Abstract][Full Text] [Related]
39. Assessing the outcomes of HIV-infected persons receiving treatment for Kaposi sarcoma in Conakry-Guinea.
Bekolo CE; Soumah MM; Tiemtore OW; Diallo A; Yuma JD; Di Stefano L; Metcalf C; Cisse M
BMC Cancer; 2017 Dec; 17(1):806. PubMed ID: 29197357
[TBL] [Abstract][Full Text] [Related]
40. Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease.
Marcelin AG; Motol J; Guihot A; Caumes E; Viard JP; Dussaix E; Cadranel J; Frances C; Carcelain G; Calvez V; Dupin N
J Infect Dis; 2007 Oct; 196(8):1163-6. PubMed ID: 17955434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
